We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+21.98%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$679M
AUM Growth
+$8.14M
Cap. Flow
+$879K
Cap. Flow %
0.13%
Top 10 Hldgs %
38.68%
Holding
124
New
21
Increased
25
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$18.7M
2
IFRX icon
InflaRx
IFRX
+$13M
3
VSTM icon
Verastem
VSTM
+$7.91M
4
AVIR icon
Atea Pharmaceuticals
AVIR
+$7.58M
5
ELEV
Elevation Oncology
ELEV
+$6.86M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$21.5M
2
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$9.81M
3
BLUE
bluebird bio
BLUE
+$9.14M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.01M
5
MRNA icon
Moderna
MRNA
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.72%
2 Financials 6.8%
3 Real Estate 0.3%
4 Consumer Discretionary 0.15%
5 Utilities 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
76
Aurinia Pharmaceuticals
AUPH
$2.11B
$1.45M 0.21%
+150,000
New +$1.56M
BOH icon
77
Bank of Hawaii
BOH
$3.13B
$1.24M 0.18%
+30,000
New +$1.33M
SFBS
78
ServisFirst Bancshares
SFBS
$4.86B
$1.23M 0.18%
30,000
– –
IVVD icon
79
Invivyd
IVVD
$218M
$1.21M 0.18%
1,151,843
+751,843
+188% +$959K
CRSP icon
80
CRISPR Therapeutics
CRSP
$5.17B
$1.12M 0.17%
+20,000
New +$1.13M
LONA
81
LeonaBio Inc
LONA
$72.1M
$1.04M 0.15%
35,272
– –
ISPO
82
DELISTED
Inspirato
ISPO
$1.01M 0.15%
51,750
+32,750
+172% +$591K
ASND icon
83
Ascendis Pharma A/S
ASND
$16.8B
$893K 0.13%
+10,000
New +$870K
NXTC icon
84
NextCure
NXTC
$26.7M
$720K 0.11%
33,333
– –
MASS icon
85
908 Devices
MASS
$364M
$686K 0.1%
+100,000
New +$804K
TNGX icon
86
Tango Therapeutics
TNGX
$4.41B
$664K 0.1%
200,000
– –
PDSB icon
87
PDS Biotechnology
PDSB
$43.4M
$503K 0.07%
+100,000
New +$655K
STEL
88
DELISTED
Stellar Bancorp
STEL
$458K 0.07%
20,000
+10,000
+100% +$233K
RNAC icon
89
Cartesian Therapeutics
RNAC
$268M
$448K 0.07%
+13,333
New +$477K
STIM icon
90
Neuronetics
STIM
$166M
$430K 0.06%
+200,000
New +$485K
WGS icon
91
GeneDx Holdings
WGS
$2.3B
$379K 0.06%
+63,636
New +$504K
ATYR
92
aTyr Pharma
ATYR
$50.1M
$324K 0.05%
150,000
+26,570
+22% +$58K
EQ icon
93
Equillium
EQ
$133M
$300K 0.04%
400,000
+311,432
+352% +$206K
PASG icon
94
Passage Bio
PASG
$14.1M
$282K 0.04%
15,000
– –
FRLN
95
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$258K 0.04%
+100,000
New +$394K
MOLN
96
Molecular Partners
MOLN
$247K 0.04%
39,753
+1,500
+4% +$9.74K
TLPH icon
97
Talphera
TLPH
$74.2M
$216K 0.03%
195,000
– –
CREG
98
DELISTED
Smart Powerr
CREG
$203K 0.03%
+1,251
New +$216K
NKTR icon
99
Nektar Therapeutics
NKTR
$2.58B
$80.3K 0.01%
9,307
– –
ALLK
100
DELISTED
Allakos
ALLK
– –
-447,967
Closed -$1.99M
1 2 3
4
5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Tang Capital Management held 124 positions worth $679M, up 1.2% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tang Capital Management's Q2 2023 filing shows 21 new, 25 increased, 15 reduced and 25 closed positions. Its largest new stake was Rain Oncology Inc. Common Stock: 3,740,341 shares worth $4.49M. The largest sale was Novo Nordisk, an estimated $21.5M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Financials and Real Estate.

  • Tang Capital Management's largest Q2 2023 buy was Rain Oncology Inc. Common Stock: 3,740,341 shares worth $4.49M.
  • Tang Capital Management added most to Atea Pharmaceuticals in Q2 2023, an estimated $7.58M increase.
  • Tang Capital Management's biggest Q2 2023 reduction was bluebird bio, cutting an estimated $9.14M.
  • Tang Capital Management fully exited Novo Nordisk in Q2 2023, selling an estimated $21.5M.
  • Tang Capital Management's ten largest holdings make up 39% of its $679M portfolio in Q2 2023.
  • Tang Capital Management opened 21 new positions and closed 25 in Q2 2023.
  • Tang Capital Management's portfolio value rose 1.2% quarter-over-quarter to $679M.

Based on Tang Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.